Purdue Pharma has developed a stable, monophasic oral pharmaceutical composition containing dronabinol for pain management and treatment of various conditions, including dementia and sleep disorders. The formulation includes specific percentages of solvents and a film-forming agent, ensuring homogeneity and stability over time. GlobalData’s report on Purdue Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Purdue Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Purdue Pharma's grant share as of June 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Cannabinoid-based oral pharmaceutical composition for pain management
The granted patent US12011430B2 outlines a pharmaceutical composition designed for oral administration, primarily containing dronabinol, a cannabinoid. The composition includes 0.25% to 2% w/w of dronabinol, a hydrophobic solvent (such as sesame oil or soybean oil) in the range of 2% to 10% w/w, and an alcohol-based solvent comprising 30% to 60% w/w. Additionally, it may contain a film-forming agent, a co-solvent, and a propellant, with the total composition being substantially anhydrous and stable as a single phase for at least two weeks at 25°C. The patent also specifies various formulations with specific percentages of these components, ensuring the composition remains stable and effective over time.
Further claims detail the inclusion of optional ingredients such as flavorants and specific types of propellants, including hydrofluoroalkanes and chlorofluorocarbons. The compositions are designed to maintain stability for extended periods, with some formulations remaining stable for up to two years at 4°C or one month at room temperature. The patent emphasizes the versatility of the composition, allowing for variations in the concentration of dronabinol, solvents, and co-solvents while ensuring the final product remains a single-phase liquid suitable for oral spray applications.
To know more about GlobalData’s detailed insights on Purdue Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
